Search Menu
Photonics Media Photonics Buyers' Guide Photonics Spectra BioPhotonics EuroPhotonics Vision Spectra Photonics Showcase Photonics ProdSpec Photonics Handbook

GE to Invest $1B in Molecular Imaging, Diagnostics

Facebook Twitter LinkedIn Email Comments
CHALFONT ST. GILES, England, Sept. 16, 2011 — GE Healthcare is set to dedicate $1 billion of its total R&D budget over the next five years to expand its advanced cancer diagnostic and molecular imaging capabilities, as well as in the company’s technologies for the manufacture of biopharmaceuticals and for cancer research.

Announced alongside a $100 million open innovation challenge in New York, the billion dollar investment crosses all lines of GE Healthcare’s global business, and will enable the company to bring the most promising cancer ideas to market, it announced.

“We are committed to tackling cancer. However, with a disease as complex and multifaceted as cancer, solutions need to be equally multifaceted and even more integrated, combining imaging, molecular diagnostics and healthcare IT,” said John Dineen, president and CEO of GE Healthcare.

GE Healthcare offers a wide portfolio for oncology and a strategy that combines cellular research, medical imaging, laboratory diagnostics, biopharmaceutical manufacturing technologies and information technology. These technologies help increase researchers’ understanding of the causes and progression of cancer and help physicians make more personalized cancer treatment and man­agement decisions, while improving clinical outcomes and accelerating the delivery of care.

For more information, visit:
Sep 2011
AmericasBiophotonicsBusinesscancer diagnosticscancer researchEnglandEuropeGE HealthcareimagingindustrialJohn Dineenlaboratory diagnosticsmedical imagingmolecular imagingNew YorkoncologyR&D expenditures

back to top
Facebook Twitter Instagram LinkedIn YouTube RSS
©2020 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA, [email protected]

Photonics Media, Laurin Publishing
x We deliver – right to your inbox. Subscribe FREE to our newsletters.
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.